• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo

tetano

Editor, Senior Moderator
Biomaterials. 2017 May 20;138:22-34. doi: 10.1016/j.biomaterials.2017.05.028. [Epub ahead of print]
[h=1]Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo.[/h] Bhatia S[SUP]1[/SUP], Lauster D[SUP]2[/SUP], Bardua M[SUP]3[/SUP], Ludwig K[SUP]4[/SUP], Angioletti-Uberti S[SUP]5[/SUP], Popp N[SUP]2[/SUP], Hoffmann U[SUP]3[/SUP], Paulus F[SUP]1[/SUP], Budt M[SUP]6[/SUP], Stadtm?ller M[SUP]6[/SUP], Wolff T[SUP]6[/SUP], Hamann A[SUP]3[/SUP], B?ttcher C[SUP]4[/SUP], Herrmann A[SUP]7[/SUP], Haag R[SUP]8[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Inhibition of influenza A virus infection by multivalent sialic acid inhibitors preventing viral hemagglutinin binding to host cells of the respiratory tract is a promising strategy. However, optimal geometry and optimal ligand presentation on multivalent scaffolds for efficient inhibition both in vitro and in vivo application are still unclear. Here, by comparing linear and dendritic polyglycerol sialosides (LPGSA and dPGSA) we identified architectural requirements and optimal ligand densities for an efficient multivalent inhibitor of influenza virus A/X31/1 (H3N2). Due to its large volume, the LPGSA at optimal ligand density sterically shielded the virus significantly better than the dendritic analog. A statistical mechanics model rationalizes the relevance of ligand density, morphology, and the size of multivalent scaffolds for the potential to inhibit virus-cell binding. Optimized LPGSA inhibited virus infection at IC[SUB]50[/SUB] in the low nanomolar nanoparticle concentration range and also showed potent antiviral activity against two avian influenza strains A/Mallard/439/2004 (H3N2) and A/turkey/Italy/472/1999 (H7N1) post infection. In vivo application of inhibitors clearly confirmed the higher inhibition potential of linear multivalent scaffolds to prevent infection. The optimized LPGSA did not show any acute toxicity, and was much more potent than the neuraminidase inhibitor oseltamivir carboxylate in vivo. Combined application of the LPGSA and oseltamivir carboxylate revealed a synergistic inhibitory effect and successfully prevented influenza virus infection in mice.
Copyright ? 2017 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Influenza virus; Ligand density; Multivalent inhibitor; Polyglycerol scaffolds; Steric shielding

PMID: 28550754 DOI: 10.1016/j.biomaterials.2017.05.028
 
Back
Top Bottom